

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

JEFFREY S. KIEL, ET AL.

Serial No.: 10/806,260

Group Art Unit: 1621

Filed: 03/22/2004

Valenrod, Yevgeny

For: PHENOLIC ACID SALTS OF GABAPENTIN :
IN LIQUID AND/OR SEMI-SOLID DOSAGE :
FORMS AND METHODS OF USE

DECLARATION OF RICHARD ANDREW TODEBUSH, PH.D.

I, Richard Andrew Todebush, Ph.D., hereby declare as follows:

1. I received a Bachelor of Science (B.S.) degree in Chemistry from Western Carolina University in 1996 and a Doctor of Philosophy (Ph.D.) in Analytical Chemistry from the University of Georgia in 2001.
2. I worked as a research chemist for Unilever, Chicago, Illinois, in the development of personal care products from 2001 to 2004. In 2004, I started working for Kiel Laboratories, Inc. (Kiel) as a Senior Research Scientist and in 2006 I became the Research and Development Manager.
3. I currently manage the Research and Development Department for Kiel Laboratories, Inc. My responsibilities include investigating new active

pharmaceutical ingredients for use in Kiel's manufacturing processes, which include the preparation of tannic acid containing compositions.

4. I have read the specification and claims of the above-referenced patent application, as well as the Office Action mailed August 27, 2007, in the present application and the prior art references cited by the Examiner.

When Drs. Jeffrey Kiel, Greg Thomas, and Narashimhan Mani made their invention of the formation of gabapentin tannate, to the best of my knowledge, there were no publications or information available that suggested it was possible to prepare a tannate salt of gabapentin.

6. Before, the invention of Dr. Kiel, et al., it was generally expected that the close proximity of the carboxylic acid group to the positively charged amine functional group on the gabapentin molecule would prevent the formation of the tannate salt. I was surprised that the inventors of the present application were able to prepare a gabapentin tannate salt.

I have reviewed U.S. Patent No. 6,383,471 ('471) to *Chen et al.* As stated in the title and throughout the Specification, it was clear to me that the '471 patent applied only to ionizable hydrophobic therapeutic agents having intrinsic water solubilities of less than 0.1% or 0.01% by weight.

8. Not knowing whether gabapentin was water-soluble, or water-insoluble, I would have checked the Merck Index or, perhaps, the Handbook of Chemistry and Physics.
9. The Merck Index has been the accepted gold standard reference for the pharmaceutical arts since 1889. Gabapentin is listed in the Merck Index as having a solubility in water at pH 7.4 which exceeds 10% (see Appendix 1). I was surprised to see gabapentin listed as one of the hydrophobic therapeutic agents in the '471 patent in col. 6, line 33; col. 7, line 2; col. 8, line 21; col. 9, line 23; col. 44, line 42; col. 45, line 12; col. 46, line 62; and col. 47, line 64. It was interesting to note that gabapentin was never included as one of the more or most preferred hydrophobic therapeutic agents.
10. In my opinion, gabapentin was mistakenly listed as a hydrophobic therapeutic agent in the '471 patent and one of ordinary skill in the art, like myself, would either have

recognized that mistake or checked the solubility in a standard reference generally used by the pharmaceutical industry such as the Merck Index.

11. It is also my opinion, that I would not have relied on the '471 patent to guide me in an attempt to prepare a gabapentin tannate salt because the '471 patent deals exclusively with hydrophobic therapeutic agents of which gabapentin is not one. I would not have noticed that gabapentin was even listed as 1 of the 300+ therapeutic agents because they were all identified as being hydrophobic. Additionally, tannic acid is identified as only 1 of 32 pharmaceutically acceptable acids. I found no suggestion in the '471 patent that tannic acid could be combined with gabapentin.
12. I have reviewed U.S. Pat. No. 6,287, 597 ('597) to *Gordziel* and I have read the Examiner's comments in the Non-final Rejection mailed August 27, 2007. The Examiner appears to be confusing the use of excipients, such magnesium aluminum silicate (MAS) in preparing suspensions, as disclosed in *Gordziel*, that already have certain tannate salts already present, with that of the invention of the present application which uses MAS to prepare the actual tannate salt of gabapentin.
13. In my opinion, if I were faced with the challenge of preparing a tannate salt of gabapentin, I would not have a reasonable expectation that a gabapentin salt could have been successfully made based on either the '471 or the '597 patent.

I declare further that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made under penalty of perjury with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 11-27-07

By: R. Andrew Todebush
Richard Andrew Todebush, Ph.D.

APPENDIX I

THE MERCK INDEX

AN ENCYCLOPEDIA OF
CHEMICALS, DRUGS, AND BIOLOGICALS

THIRTEENTH EDITION

Editorial Staff

Maryadele J. O'Neil, Senior Editor

Ann Smith, Senior Associate Editor

Patricia E. Heckelman, Associate Editor

John R. Obenchain Jr., Editorial Assistant

Jo Ann R. Gallipeau, Technical Assistant

Mary Ann D'Alecca, Administrative Associate


Susan Budavari, Editor Emeritus

*Published by
Merck Research Laboratories
Division of*

MERCK & CO., INC.
Whitehouse Station, NJ

2001


4343. Gabapentin. [50142-96-5] 1-(Aminomethyl)-cyclohexanecarboxylic acid, Cf-943; Gb-3450; GOS-3450; Neurontin. $C_8H_{15}NO_2$, mol wt 171.24. C 63.13%, H 10.01%, N 8.18%, O 8.69%. Amino acid structurally related to γ -aminobutyric acid (GABA), q.v., designed to cross the blood brain barrier. Syn: G. Satzing et al., DE 2460891 (1976 to Glödecke); *exam.* US 4024175 (1977 to Warner-Lambert). Pharmacokinetics and metabolism: K.-O. Vollmer et al., *Arzneimittelforsch.* 36, 830 (1986). Clinical pharmacology: B. Saleu et al., *Int. J. Clin. Pharmacol. Ther. Toxicol.* 24, 352 (1986). GC determination in biological fluids: W. D. Hooper et al., *J. Chromatog.* 52, 167 (1990). Review of pharmacology and clinical trials in epilepsy: B. Schmidt in *Antiepileptic Drugs*, R. H. Levy et al., Eds. (Raven Press, New York, 3rd ed., 1989) pp 925-935; K. I. Goa, E. M. Sorkin, *Drugs* 46, 409-427 (1993). Clinical trial for treatment of pain in diabetic neuropathy: M. Beckouja et al., *J. Am. Med. Assoc.* 280, 1831 (1998). Clinical evaluation of social phobia: A. C. Parde et al., *J. Clin. Psychopharmacol.* 19, 341 (1999).



Protonic pK_a values: pK_{a1} 152-166° (Satzinger); also reported at pK_{a1} 177-177° (Schmidt). pK_{a2} (25°) 3.68; pK_{a2} 10.70. Infrared: ν_{max} 3400. Solubility in water at pH 7.4 exceeds 10%.


Uses: 1. Anticonvulsant

4343. Gabexate. [59492-01-8] 4-[[6-[(Aminomino-methyl)amino] 1-oxohexyl]oxy]benzoic acid ethyl ester; *p*-hydroxybenzoic acid ethyl ester 6-guanidinohexanoate; *p*-carbethoxyphenyl 6-guanidinohexanoate. $C_{21}H_{32}N_4O_6$, mol wt 321.37. C 59.60%, H 7.21%, N 13.08%, O 19.91%. Non-peptide proteolytic enzyme inhibitor which also inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, trypsin but not chymotrypsin; *cf.* aprotinin. Prep: as the *p*-toluenesulfonate salt: S. Fujii, T. Watanabe, DE 2050484; *idem.* US 3751447 (1971, 1977 both to Ono). Enzyme inhibition: M. Muramatsu, S. Fujii, *Biochim. Biophys. Acta* 268, 221 (1972); S. Tamura et al., *ibid.* 484, 417 (1977). Pharmacology: T. Okegami et al., *Nippon Jikeigaku Zasshi* 71, 71 (1975); C.A. 84, 218m (1976). Mechanism: M. Sugiyama et al., *Oyo Yakuri* 9, 733 (1975); C.A. 63, 188145t (1975). Metabolism of inhibitory effect on platelet aggregation: O. Kosaki et al., *Thromb. Res.* 20, 587 (1980). Beneficial action in traumatic shock: A. M. Lefer et al., *IRCS J. Surg. Sci. Lib. Commun.* 8, 278 (1980); in exptl acute pancreatitis: J. R. Winters et al., *Pancreas* 2, 181 (1987). Comparative clinical study in acute pancreatitis: N. Tanaka et al., *Adv. Enz. Mol. Biol.* 120, 367 (1979). Toxicology and toxicity study: S. Fujii et al., *Oyo Yakuri* 9, 743 (1975); C.A. 83, 188322x (1975).



Methanesulfonate. [56974-61-9] Gabexate mesylate; FOM; Megacort. $C_{21}H_{32}N_4O_6 \cdot CH_3SO_3H$; mol wt 417.48. White crystals. Sol in water, ethanol, chloroform. Slightly sol in acetone. Practically insol in ether. pH of soln (1:100): 4.0-5.0. LD_{50} in mice (mg/kg): 8000 orally; 4700 i.v.; 25 i.v. (Fujita). THERAP CAT: Enzyme inhibitor (proteinase).


4344. Gadobenate-Dimeglumine. [127000-20-8] 1-Deoxy-1-(methylamino)-D-glucitol [4-(carboxy- κ O)-5,8,11-tris-[(carboxy- κ O)methyl]-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oxo(5-)- κ N³, κ N⁴, κ N¹⁰, κ O¹³]gadolinium(2-); (2:1), gadolinium benzyloxypropionictetraacetate dimeglumine; Gd-BOPTA/Dimeg; B-190367; MultiHance. $C_{26}H_{43}GdN_3O_{21}$, mol wt 1058.28. C 40.85%, H 5.92%, Gd 14.86%, N 6.62%, O 31.75%. $C_{22}H_{26}GdN_3O_{11} \cdot 2C_2H_5NO_2 \cdot 2H_2O$. Intravascular paramagnetic MRI contrast agent. Prep: E. Felder et al., EP 230893; *idem.* US 4916246 (1987, 1990 both to Bracco); F. Ungeri et al., *Inorg. Chem.* 34, 633 (1995). HPLC determination in biological samples: T. Artughi et al., *J. Chromatog. B* 713, 415 (1998). Physicochemical properties: C. de Haen et al., *J. Computer Assist. Tomog.* 23, Suppl. 1, S161 (1999). Pharmacology: P. Thronc et al., *ibid.* S195. Pharmacokinetics: V. Lorusso et al., *ibid.* S181. Toxicology: A. Morisotti et al., *ibid.* S207. Clinical study in MRI of liver lesions: J. Petersen et al., *Radiology* 215, 727 (2000). Review of clinical studies: B. Hamm et al., *J. Computer Assist. Tomog.* 23, Suppl. 1, S53-S60 (1999).



Hygroscopic powder. mp 124°. Freely sol in water, sol in methanol. Practically insol in *n*-butanol, *n*-octanol, chloroform. Abs max 257.8 nm (ϵ 203). $[\alpha]_D^{25}$ -26.9° (c = 1.45 in water). Prep: as 0.5M soln, osmolality (37°) 1.97 mol/kg. d_{20}^{20} 1.22. Viscosity (mPa.s): 9.2 (20°), 5.3 (37°). LD_{50} i.v. in mice (mmol/kg): 5.7 (at 1 mL/min), 7.9 (at 0.2 mL/min); LD_{50} i.v. in rats (mmol/kg): 6.6 (at 6 mL/min), 9.2 (at 1 mL/min) (Morisotti).

THERAP CAT: Diagnostic aid (MRI contrast agent).

4345. Gadobutrol. [138071-82-6] [10-[2,3-Dihydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)- $N^1,N^4,N^7,N^{10},O^1,O^4,O^7$]gadolinium; Gd-DO3A-butrol; Gadovist. $C_{31}H_{51}GdN_4O_{19}$, mol wt 604.78. C 35.75%, H 5.18%, Gd 26.00%, N 9.27%, O 23.81%. Neutral, macrocyclic gadolinium chelate. Prep: J. Plazek et al., EP 448191 (1991 to Schering AG). Physicochemical properties and *in vivo* imaging studies: H. Vogler et al., *Eur. J. Radiol.* 21, 1 (1995). Clinical pharmacokinetics: T. Stinks et al., *Invest. Radiol.* 29, 709 (1994). Clinical evaluation of diagnostic use for cerebral metastases: T. J. Vogl et al., *Radiologe* 35, 508 (1995); for glioblastomas: M. Hornmann et al., *Fortschr. Röntgenstr.* 164, 119 (1996).



Hydrophilic. Osmolality (osmol/kg): 0.57 (0.5 mol/l); 1.39 (1 mol/l). Viscosity (cP): 1.43 (0.5 mol/l); 3.7 (1 mol/l). Partition coefficient (butanol/water): 0.006. LD_{50} i.v. in mice: 23 mmol/kg (Vogler).

THERAP CAT: Diagnostic aid (MRI contrast agent).

4346. Gadodiamide. [131410-48-5] [5,8-Bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetrazatridecan-13-oxo(3-)]gadolinium; gadolinium diethyle-